EUVIMEDEUVIMED entdecken
Editorial

Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?

Wadih Arap iD, Renata Pasqualini, Isan Chen

JCO Clinical Cancer Informatics · 2026-07 · 10 (3)

DOI: 10.1200/cci-26-00178 ↗

Kurz gefasst

Editorial in der Zeitschrift JCO Clinical Cancer Informatics, 2026-07. Verfasst von Wadih Arap und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute, Newark, NJ. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Rutgers Cancer Institute, Newark, NJ.
  • Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ.
  • Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ.
  • MBrace Therapeutics, San Diego, CA.

ORCID-Profile: Wadih Arap

Zitieren

APA

Arap, W., Pasqualini, R., & Chen, I. (2026). Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?. JCO Clinical Cancer Informatics, 10(3). https://doi.org/10.1200/cci-26-00178

Vancouver

Arap W, Pasqualini R, Chen I. Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?. JCO Clinical Cancer Informatics. 2026;10(3). doi:10.1200/cci-26-00178

BibTeX
@article{Arap2026,
  author = {Arap, Wadih and Pasqualini, Renata and Chen, Isan},
  title = {Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?},
  journal = {JCO Clinical Cancer Informatics},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.1200/cci-26-00178}
}
Kostenlos starten →